How much funding has CancerVAX raised?

CancerVAX has disclosed $1M raised across 1 round.

Where is CancerVAX headquartered?

CancerVAX is headquartered in Santa Barbara, US.

CancerVAX

Santa Barbara, US · Founded 2021 · Nevada corporation

CancerVax is a pre-clinical biotech company developing a customizable, AI-supported cancer immunotherapy platform delivered as an injection, designed to disguise cancer cells as a familiar virus (such as measles) so the body's immune system recognizes and kills them. The platform aims to treat many types of cancer and is being developed with partners including Cytiva and TriLink BioTechnologies.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Byron EltonExecutive

Board

Carla MillerBoard director

Reported raises · per SEC filings

Form D private placements

$1M disclosed across 1 round · 2023

▶$1MraisedOct 2024 · 1 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Carla MillerDirector
Byron EltonExecutive Officer, Director

Offering amount: $10M
Amount sold: $1M
Minimum investment: $100K
First sale: Oct 2023
Incorporated: Corporation, Nevada, 2021
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Imvax35 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.

Dynavax NASDAQ: DVAX www.dynavax.com23 shared keywordsDynavax is a biopharmaceutical company that develops and commercializes vaccines to protect against infectious diseases, including HEPLISAV-B, a two-dose adult hepatitis B vaccine, and its CpG 1018 adjuvant used in multiple vaccines. The company also advances a pipeline of novel vaccine clinical candidates.

Vaccinex20 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.

Centivax18 shared keywordsCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.

Companies competing with CancerVAX for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does CancerVAX do?: CancerVax is a pre-clinical biotech company developing a customizable, AI-supported cancer immunotherapy platform delivered as an injection, designed to disguise cancer cells as a familiar virus (such as measles) so the body's immune system recognizes and kills them. The platform aims to treat many types of cancer and is being developed with partners including Cytiva and TriLink BioTechnologies.
How much funding has CancerVAX raised?: CancerVAX has disclosed $1M raised across 1 round.
Where is CancerVAX headquartered?: CancerVAX is headquartered in Santa Barbara, US.